Developer docs
API playgroundTry for free, no card

Search company profiles

CND Life Sciences

Full company profile

uuid00005re

Namestring
CND Life Sciences
Legal namestring
CND Life Sciences, Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

CND Life Sciences is a Scottsdale, Arizona-based medical technology company founded in 2020 that has developed the Syn-One Test, the first commercially available skin-based diagnostic for detecting phosphorylated alpha-synuclein in cutaneous nerve fibers to aid in the diagnosis of Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure. The test uses a minimally invasive skin biopsy analyzed via immunofluorescence in the company's CLIA-certified, CAP-accredited laboratory, reporting >95% sensitivity and specificity, and has been ordered nearly 50,000 times in the U.S. by 3,500+ neurologists. The company supplements its clinical diagnostic franchise with a Small-Fiber Dx test for peripheral neuropathy and a Syn-One Biomarker Services offering that supplies biopharmaceutical companies with biomarker analysis for Parkinson's disease clinical trials, including the ABLi Therapeutics Phase 2 risvodetinib study.

The company generates revenue primarily through per-test laboratory diagnostic services paid by Medicare and other payers, supplemented by contract research revenue from biopharma biomarker services. Distribution is direct-to-clinician via a kit ordering system, with patient self-pay available as a secondary channel, and direct enterprise engagement with pharmaceutical trial sponsors. The business operates from CLIA-certified laboratory facilities in Scottsdale and Boston, with additional offices in Atlanta and Brookline, and holds state-level clinical laboratory licenses in New York, California, Maryland, Pennsylvania, and Rhode Island. CND is venture-backed with cumulative equity exceeding $20M led by a $13.5M Series A in May 2025 with Labcorp, supplemented by approximately $8.4M in NIH grants, and is led by physician-scientist co-founders from Harvard Medical School, Beth Israel Deaconess Medical Center, and HonorHealth, with a commercial organization in active buildout under a newly hired SVP, Commercial.

Short descriptiontext

CND Life Sciences is a Scottsdale-based medical technology company that operates a CLIA-certified laboratory providing the Syn-One Test, a skin biopsy-based diagnostic for detecting phosphorylated alpha-synuclein to diagnose Parkinson's disease and related synucleinopathies for neurologists and biopharmaceutical sponsors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersScottsdale, United States
HQ citystring
Scottsdale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurological diagnostic testing, skin biopsy diagnostics, clinical laboratory services, biomarker assay development, neurodegenerative disease diagnostics
Industry3 codes
PRIMARYHLAFAKAK
Neurodiagnostic Centers (EEG/EMG/NCS)
SECONDARYHLAKAIAC
Movement Disorders (Parkinson’s, Tremor, Dystonia)
SECONDARYHLAKAIAO
Neurogenetics & Rare Neurologic Diseases
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Neurological Diagnostic Laboratory Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Clinical Diagnostic Testing
TypeOne Time License
Description

CND provides laboratory testing services through its CLIA-certified and CAP-accredited laboratory. Clinicians order skin biopsy test kits, collect samples from patients, and send them to CND for analysis. Results are reported back to clinicians to support diagnostic decision-making. Revenue is generated per test performed, with Medicare coverage established and commercial payer relationships being developed.

cndlifesciences.com
2Biomarker Services for Biopharma
TypeProfessional Services
Description

CND offers biomarker analysis services to pharmaceutical companies conducting clinical trials for neurodegenerative disease therapeutics. The company's Syn-One test is used as a biomarker endpoint in drug trials, such as the ABLi Therapeutics Phase 2 trial for risvodetinib, generating contract research revenue.

prnewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1Laboratory testing services for neurodegenerative disease diagnosis
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed. Medicare coverage established. Self-pay option available for patients.

cndlifesciences.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Syn-One Test
Description

The first commercially available skin-based test to help clinicians diagnose Parkinson's disease and related disorders by detecting phosphorylated alpha-synuclein in skin biopsies.

cndlifesciences.com
+2 more records
Core offering1 text field

CND Life Sciences operates a CLIA-certified, CAP-accredited diagnostic laboratory that provides the Syn-One Test, a skin biopsy-based assay detecting phosphorylated alpha-synuclein in cutaneous nerve fibers to help clinicians diagnose Parkinson's disease and related synucleinopathies, plus Small-Fiber Dx for peripheral neuropathy assessment. The company also delivers Syn-One Biomarker Services to biopharmaceutical companies for use as endpoints and patient stratification tools in neurodegenerative disease clinical trials, leveraging its NerValence AI-assisted digital pathology platform co-developed with Visiopharm.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Skin biopsy findings influenced patient management in 71.2% of cases (52/73)
+4 more records
Product overview1 text field

CND Life Sciences offers a portfolio of skin-based neurodiagnostic tests and biomarker services. The flagship product is the Syn-One Test, the first commercially available skin-based test to detect phosphorylated alpha-synuclein in cutaneous nerve fibers to aid diagnosis of Parkinson's disease and other synucleinopathies. The company also provides Small-Fiber Dx for evaluating small fiber neuropathy when nerve conduction studies are normal. Through its Biopharma division, CND offers Syn-One Biomarker Services for pharmaceutical clinical trials, utilizing its AI-assisted digital pathology tool NerValence (developed with Visiopharm) to analyze skin biopsy samples.

Product and service3 records
1Syn-One Test
CategoryCore diagnostic test (skin biopsy-based biomarker assay)
Description

The first commercially available skin-based diagnostic test that uses a minimally invasive skin biopsy and immunofluorescence to detect phosphorylated alpha-synuclein (P-SYN) in cutaneous nerve fibers, helping clinicians diagnose Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, and related synucleinopathies. The test has >95% sensitivity and specificity, has been ordered nearly 50,000 times in the U.S., is covered by Medicare, and is used by 3,500+ U.S. neurologists.

2Small-Fiber Dx
CategoryCore diagnostic test (peripheral nerve fiber analysis)
Description

A diagnostic test for evaluating small fiber neuropathy when standard nerve conduction studies are normal but patients may still have isolated small fiber neuropathy. The test assesses small nerve fiber dysfunction, including intra-epidermal nerve fiber density, to support diagnosis of peripheral neuropathy conditions.

3Syn-One Biomarker Services
CategoryClinical research services / biomarker services for biopharma
Description

Biomarker analysis services offered to biopharmaceutical companies for use in clinical trials, enabling measurement of phosphorylated alpha-synuclein in skin biopsies as trial endpoints or patient stratification tools. Leverages the proprietary NerValence AI-assisted digital pathology tool (developed in collaboration with Visiopharm) for enhanced precision and consistency.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-11
Description

CND's Syn-One Biomarker Services were used in ABLi Therapeutics' Phase 2 clinical trial for their Parkinson's disease drug candidate risvodetinib. Analysis of 36 subjects showed a reduction in phosphorylated alpha-synuclein deposition over 12 weeks, marking the first-ever measure of its kind to demonstrate a possible treatment effect on intra-neuronal synuclein deposition in a Parkinson's disease drug trial.

Strategic tierCoreTypeTechnology or Integration
Description

CND collaborated with Denmark-based Visiopharm to develop NerValence, an AI-assisted digital pathology tool used to analyze skin biopsy samples with enhanced precision and consistency.

Strategic tierMinorTypeOthers
Description

Indie Studios provides co-working office space for CND's Atlanta location at 190 Ottley Drive NE, Suite J, Atlanta, GA 30324-3925.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Roche develops Elecsys CSF-based biomarker assays for Alzheimer's and is developing alpha-synuclein diagnostic assays through Roche Tissue Diagnostics. A broad incumbent in CNS biomarker diagnostics with global scale and an active pharmaceutical companion diagnostic pipeline.

TypeBroad incumbent
Description

Labcorp is a leading global clinical laboratory services company and CND's lead Series A investor. Operates extensive neurological and neurodegenerative disease testing menus and could be both a channel partner and a competitor if it internalizes similar P-SYN testing capabilities.

TypeBroad incumbent
Description

Quanterix develops the Simoa single-molecule array platform for ultra-sensitive biomarker detection, used in neurodegenerative disease research and diagnostics. Comparable to CND as an enabling ultra-sensitive biomarker detection platform serving both research and clinical neurodiagnostic applications.

TypeBroad incumbent
Description

Quest Diagnostics is one of the largest U.S. clinical laboratory networks, offering neurological and genetic testing services through its Athena Diagnostics specialty neurology division. Represents both an established competitor in the neurology diagnostics market and a potential strategic acquirer.

TypeDirect peer
Description

Amprion develops SAAmplify, a CSF-based alpha-synuclein aggregation assay (PMCA/RT-QuIC technology) for diagnosing synucleinopathies. Direct competitor to CND's Syn-One, addressing the same clinical question of pathological synuclein detection but using cerebrospinal fluid rather than skin biopsies.

TypeBroad incumbent
Description

ARUP Laboratories is a national reference laboratory affiliated with the University of Utah, offering specialized neurological and neurogenetic testing panels. Comparable to CND as a specialty neurodiagnostic reference lab serving academic medical centers and clinicians nationwide.

TypeBroad incumbent
Description

Mayo Clinic Laboratories operates a major reference laboratory offering extensive neurological and neurodegenerative disease testing panels, including alpha-synuclein and related biomarker assays. Established broad incumbent in the same clinical neurodiagnostic market CND serves, with significantly greater scale and payer relationships.

TypeDirect peer
Description

C2N Diagnostics offers PrecivityAD, a blood-based biomarker test for Alzheimer's disease pathology, and is expanding into neurodegenerative disease diagnostics via mass spectrometry-based assays. Highly comparable to CND's model of objective blood/tissue-based biomarker diagnostics for neurodegenerative disease serving neurologists and biopharma.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CND Life Sciences

Neurological Diagnostic Laboratory Servicescndlifesciences.com

CND Life Sciences is a Scottsdale-based medical technology company that operates a CLIA-certified laboratory providing the Syn-One Test, a skin biopsy-based diagnostic for detecting phosphorylated alpha-synuclein to diagnose Parkinson's disease and related synucleinopathies for neurologists and biopharmaceutical sponsors.

What CND Life Sciences does

CND Life Sciences is a Scottsdale, Arizona-based medical technology company founded in 2020 that has developed the Syn-One Test, the first commercially available skin-based diagnostic for detecting phosphorylated alpha-synuclein in cutaneous nerve fibers to aid in the diagnosis of Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure. The test uses a minimally invasive skin biopsy analyzed via immunofluorescence in the company's CLIA-certified, CAP-accredited laboratory, reporting >95% sensitivity and specificity, and has been ordered nearly 50,000 times in the U.S. by 3,500+ neurologists. The company supplements its clinical diagnostic franchise with a Small-Fiber Dx test for peripheral neuropathy and a Syn-One Biomarker Services offering that supplies biopharmaceutical companies with biomarker analysis for Parkinson's disease clinical trials, including the ABLi Therapeutics Phase 2 risvodetinib study.

The company generates revenue primarily through per-test laboratory diagnostic services paid by Medicare and other payers, supplemented by contract research revenue from biopharma biomarker services. Distribution is direct-to-clinician via a kit ordering system, with patient self-pay available as a secondary channel, and direct enterprise engagement with pharmaceutical trial sponsors. The business operates from CLIA-certified laboratory facilities in Scottsdale and Boston, with additional offices in Atlanta and Brookline, and holds state-level clinical laboratory licenses in New York, California, Maryland, Pennsylvania, and Rhode Island. CND is venture-backed with cumulative equity exceeding $20M led by a $13.5M Series A in May 2025 with Labcorp, supplemented by approximately $8.4M in NIH grants, and is led by physician-scientist co-founders from Harvard Medical School, Beth Israel Deaconess Medical Center, and HonorHealth, with a commercial organization in active buildout under a newly hired SVP, Commercial.

CND Life Sciences firmographics

Firmographics
Name
CND Life Sciences
Legal name
CND Life Sciences, Inc.
Website
https://cndlifesciences.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
101–250 employees
Short description
CND Life Sciences is a Scottsdale-based medical technology company that operates a CLIA-certified laboratory providing the Syn-One Test, a skin biopsy-based diagnostic for detecting phosphorylated alpha-synuclein to diagnose Parkinson's disease and related synucleinopathies for neurologists and biopharmaceutical sponsors.
Ownership category
akta.pro rank

CND Life Sciences industry classification

Industry
Product category
Neurological Diagnostic Laboratory Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAFAKAK
Neurodiagnostic Centers (EEG/EMG/NCS)
SECONDARYHLAKAIAC
Movement Disorders (Parkinson’s, Tremor, Dystonia)
SECONDARYHLAKAIAO
Neurogenetics & Rare Neurologic Diseases

Keywords

  • Neurological diagnostic testing
  • Skin biopsy diagnostics
  • Clinical laboratory services
  • Biomarker assay development
  • Neurodegenerative disease diagnostics

Where CND Life Sciences is headquartered

Location

Headquarters

HQ city
Scottsdale
HQ country
United States
HQ region
North America

Offices4 records

Markets served

CND Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Clinical Diagnostic Testing: CND provides laboratory testing services through its CLIA-certified and CAP-accredited laboratory. Clinicians order skin biopsy test kits, collect samples from patients, and send them to CND for analysis. Results are reported back to clinicians to support diagnostic decision-making. Revenue is generated per test performed, with Medicare coverage established and commercial payer relationships being developed.
  2. Biomarker Services for Biopharma: CND offers biomarker analysis services to pharmaceutical companies conducting clinical trials for neurodegenerative disease therapeutics. The company's Syn-One test is used as a biomarker endpoint in drug trials, such as the ABLi Therapeutics Phase 2 trial for risvodetinib, generating contract research revenue.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goLaboratory testing services for neurodegenerative disease diagnosis

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

CND Life Sciences product offering

Product offering

Core offering

CND Life Sciences operates a CLIA-certified, CAP-accredited diagnostic laboratory that provides the Syn-One Test, a skin biopsy-based assay detecting phosphorylated alpha-synuclein in cutaneous nerve fibers to help clinicians diagnose Parkinson's disease and related synucleinopathies, plus Small-Fiber Dx for peripheral neuropathy assessment. The company also delivers Syn-One Biomarker Services to biopharmaceutical companies for use as endpoints and patient stratification tools in neurodegenerative disease clinical trials, leveraging its NerValence AI-assisted digital pathology platform co-developed with Visiopharm.

Product overview

CND Life Sciences offers a portfolio of skin-based neurodiagnostic tests and biomarker services. The flagship product is the Syn-One Test, the first commercially available skin-based test to detect phosphorylated alpha-synuclein in cutaneous nerve fibers to aid diagnosis of Parkinson's disease and other synucleinopathies. The company also provides Small-Fiber Dx for evaluating small fiber neuropathy when nerve conduction studies are normal. Through its Biopharma division, CND offers Syn-One Biomarker Services for pharmaceutical clinical trials, utilizing its AI-assisted digital pathology tool NerValence (developed with Visiopharm) to analyze skin biopsy samples.

Differentiator

Problem solved

Functional benefit

Brands

  • Syn-One Test: The first commercially available skin-based test to help clinicians diagnose Parkinson's disease and related disorders by detecting phosphorylated alpha-synuclein in skin biopsies.
  • Small-Fiber Dx
  • Syn-One Biomarker Services

Products and services

  • Syn-One Test The first commercially available skin-based diagnostic test that uses a minimally invasive skin biopsy and immunofluorescence to detect phosphorylated alpha-synuclein (P-SYN) in cutaneous nerve fibers, helping clinicians diagnose Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, and related synucleinopathies. The test has >95% sensitivity and specificity, has been ordered nearly 50,000 times in the U.S., is covered by Medicare, and is used by 3,500+ U.S. neurologists.
  • Small-Fiber Dx A diagnostic test for evaluating small fiber neuropathy when standard nerve conduction studies are normal but patients may still have isolated small fiber neuropathy. The test assesses small nerve fiber dysfunction, including intra-epidermal nerve fiber density, to support diagnosis of peripheral neuropathy conditions.
  • Syn-One Biomarker Services Biomarker analysis services offered to biopharmaceutical companies for use in clinical trials, enabling measurement of phosphorylated alpha-synuclein in skin biopsies as trial endpoints or patient stratification tools. Leverages the proprietary NerValence AI-assisted digital pathology tool (developed in collaboration with Visiopharm) for enhanced precision and consistency.

Quantifiable outcome

  • Skin biopsy findings influenced patient management in 71.2% of cases (52/73)
  • +4 more outcomes

Companies that use CND Life Sciences

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles2 records

CND Life Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

CND Life Sciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • ABLi TherapeuticscoreStrategic or Co-development Partner · 11 November 2025CND's Syn-One Biomarker Services were used in ABLi Therapeutics' Phase 2 clinical trial for their Parkinson's disease drug candidate risvodetinib. Analysis of 36 subjects showed a reduction in phosphorylated alpha-synuclein deposition over 12 weeks, marking the first-ever measure of its kind to demonstrate a possible treatment effect on intra-neuronal synuclein deposition in a Parkinson's disease drug trial.
  • Visiopharm (Denmark)coreTechnology or IntegrationCND collaborated with Denmark-based Visiopharm to develop NerValence, an AI-assisted digital pathology tool used to analyze skin biopsy samples with enhanced precision and consistency.
  • Indie StudiosminorOthersIndie Studios provides co-working office space for CND's Atlanta location at 190 Ottley Drive NE, Suite J, Atlanta, GA 30324-3925.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

CND Life Sciences competitors and assessment

Company assessment

Broad incumbents

  • Roche Diagnostics: Roche develops Elecsys CSF-based biomarker assays for Alzheimer's and is developing alpha-synuclein diagnostic assays through Roche Tissue Diagnostics. A broad incumbent in CNS biomarker diagnostics with global scale and an active pharmaceutical companion diagnostic pipeline.
  • Labcorp: Labcorp is a leading global clinical laboratory services company and CND's lead Series A investor. Operates extensive neurological and neurodegenerative disease testing menus and could be both a channel partner and a competitor if it internalizes similar P-SYN testing capabilities.
  • Quanterix: Quanterix develops the Simoa single-molecule array platform for ultra-sensitive biomarker detection, used in neurodegenerative disease research and diagnostics. Comparable to CND as an enabling ultra-sensitive biomarker detection platform serving both research and clinical neurodiagnostic applications.
  • Quest Diagnostics: Quest Diagnostics is one of the largest U.S. clinical laboratory networks, offering neurological and genetic testing services through its Athena Diagnostics specialty neurology division. Represents both an established competitor in the neurology diagnostics market and a potential strategic acquirer.
  • ARUP Laboratories: ARUP Laboratories is a national reference laboratory affiliated with the University of Utah, offering specialized neurological and neurogenetic testing panels. Comparable to CND as a specialty neurodiagnostic reference lab serving academic medical centers and clinicians nationwide.
  • Mayo Clinic Laboratories: Mayo Clinic Laboratories operates a major reference laboratory offering extensive neurological and neurodegenerative disease testing panels, including alpha-synuclein and related biomarker assays. Established broad incumbent in the same clinical neurodiagnostic market CND serves, with significantly greater scale and payer relationships.

Direct peers

  • Amprion: Amprion develops SAAmplify, a CSF-based alpha-synuclein aggregation assay (PMCA/RT-QuIC technology) for diagnosing synucleinopathies. Direct competitor to CND's Syn-One, addressing the same clinical question of pathological synuclein detection but using cerebrospinal fluid rather than skin biopsies.
  • C2N Diagnostics: C2N Diagnostics offers PrecivityAD, a blood-based biomarker test for Alzheimer's disease pathology, and is expanding into neurodegenerative disease diagnostics via mass spectrometry-based assays. Highly comparable to CND's model of objective blood/tissue-based biomarker diagnostics for neurodegenerative disease serving neurologists and biopharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

CND Life Sciences social profiles

Digital presence

CND Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CND Life Sciences leadership team

Management profile

Number of profiles

Profiles17 records

CND Life Sciences funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CND Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CND Life Sciences

What does CND Life Sciences do?

CND Life Sciences operates a CLIA-certified, CAP-accredited diagnostic laboratory that provides the Syn-One Test, a skin biopsy-based assay detecting phosphorylated alpha-synuclein in cutaneous nerve fibers to help clinicians diagnose Parkinson's disease and related synucleinopathies, plus Small-Fiber Dx for peripheral neuropathy assessment. The company also delivers Syn-One Biomarker Services to biopharmaceutical companies for use as endpoints and patient stratification tools in neurodegenerative disease clinical trials, leveraging its NerValence AI-assisted digital pathology platform co-developed with Visiopharm.

Is CND Life Sciences a public or private company?

CND Life Sciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was CND Life Sciences founded?

CND Life Sciences was founded in 2020. It employs 101 to 250 people.

Where is CND Life Sciences based?

CND Life Sciences is headquartered in Scottsdale, United States, in the North America region.

How does CND Life Sciences make money?

Two revenue lines are on record. Clinical Diagnostic Testing is the primary driver. The others are biomarker Services for Biopharma.

Who are CND Life Sciences's main competitors?

Broad incumbents on record are Roche Diagnostics, Labcorp, Quanterix, Quest Diagnostics, ARUP Laboratories and Mayo Clinic Laboratories. Direct peers are Amprion and C2N Diagnostics.

Does CND Life Sciences have an API?

No public API is recorded for CND Life Sciences.

What industry is CND Life Sciences in?

CND Life Sciences's product category is Neurological Diagnostic Laboratory Services. Its primary akta.pro industry code is HLAFAKAK, Neurodiagnostic Centers (EEG/EMG/NCS), with a secondary code of HLAKAIAC, Movement Disorders (Parkinson’s, Tremor, Dystonia). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyCND Life Sciences opens new neurodiagnostics labCND Life Sciences opened a new neurodiagnostics lab in Scottsdale, Arizona, on 17 September, with operations starting the following week. The lab will support assay development, biomarker research, and translational work, separate from its clinical testing lab. The company also plans to explore novel therapeutic treatments for degenerative diseases.Longevity.TechnologyCND Life Sciences opens Innovation Laboratory in ScottsdaleCND Life Sciences opened an Innovation Laboratory in Scottsdale on September 17, 2026, with a ribbon-cutting ceremony. The facility will support assay development, biomarker research, and translational programs, separate from its CLIA-certified clinical lab. Operations begin next week.Longevity.TechnologyCND Life Sciences funding backs earlier Parkinson’s detectionCND Life Sciences announced growth financing led by S-Curve Partners, with participation from existing investors, to expand its Syn-One Test platform for detecting synucleinopathies including Parkinson's via skin biopsy. The test has evaluated over 60,000 patients since 2020 and is used by more than 4,000 clinicians in the US. CND plans to evolve it into a multimodal biomarker platform.Neurology liveSyn-One Test Reports High Sensitivity and Specificity Across Multiple SynucleinopathiesCND Life Sciences reported that its Syn-One Test, a skin biopsy for detecting alpha-synuclein pathology, achieved 95.5% sensitivity and 96.7% specificity across various synucleinopathies including Parkinson disease and multiple system atrophy. The findings, presented at the 2023 American Academy of Neurology Annual Meeting, highlight the test's ability to reduce misdiagnosis rates which can reach 30%. This validation supports the use of cutaneous biomarkers for improving clinical diagnosis and advancing drug development for neurodegenerative diseases.Neurology liveSyn-One Test Displays Significant Clinical Utility for the Diagnosis of SynucleinopathiesA study published in Frontiers in Neurology indicates that the Syn-One Test by CND Life Sciences significantly altered clinical care for 78% of patients with suspected synucleinopathies, including changes in diagnosis and treatment plans. The test, which detects phosphorylated α-synuclein via skin biopsy, was evaluated on 97 patients at Beth Israel Deaconess Medical Center to assess its impact on diagnostic accuracy and management decisions. Researchers concluded that the tool enhances clinical decision-making and facilitates referrals to specialized therapies for conditions such as Parkinson's disease and Lewy body dementia.Neurology liveUse of Skin Biopsy Test Reduces Neurological Health Care Costs in Suspected SynucleinopathiesA retrospective study presented at the 2026 AD/PD International Conference found that using CND Life Sciences' Syn-One skin biopsy test for suspected synucleinopathies significantly reduced neurological health care costs by decreasing reliance on expensive neuroimaging and referrals. The research, involving 100 patients in a private practice, demonstrated an annualized cost reduction of $100,521 per patient after the implementation of P-SYN testing. This efficiency gain supports the clinical utility of the test, which received FDA breakthrough device designation in October 2025.Pulse 2.0CND Life Sciences Receives Growth Financing Led By S-Curve PartnersCND Life Sciences has secured growth financing led by S-Curve Partners to expand the commercial adoption of its Syn-One Test and develop a broader neurodiagnostics platform. The company intends to use the funds for product development, strategic partnerships, and integration into multimodal biomarker solutions for diagnosing neurodegenerative diseases. This investment supports CND's efforts to enhance clinical access and strengthen relationships with biopharmaceutical partners.Sleep ReviewGrowth Financing Secured to Expand Syn-One Test PlatformCND Life Sciences has secured growth financing led by S-Curve Partners to expand its commercial operations and innovation for the Syn-One Test platform. The funds will support the expansion of this skin biopsy-based diagnostic tool, which detects abnormal alpha-synuclein to aid in evaluating conditions like REM sleep behavior disorder and Parkinson's disease across the US.Longevity.TechnologyCND Life Sciences secures funding to expand Parkinson’s and neurodegenerative testCND Life Sciences completed a growth financing round led by S-Curve Partners, with participation from existing investors and shareholders, to accelerate expansion of its Syn-One Test platform for neurodegenerative disease diagnosis. The Syn-One Test, which detects abnormal phosphorylated alpha-synuclein and other pathological markers, has been utilized by over 4,000 neurologists to evaluate more than 60,000 patients in the United States since 2020. Proceeds will support commercial expansion, product innovation, strategic partnerships, and integration into a broader multimodal biomarker capability for clinical diagnosis of neurodegenerative disorders.Clinical Lab ProductsCND Life Sciences Secures Funding to Expand Syn-One NeurodiagnosticsCND Life Sciences completed growth financing led by S-Curve Partners to expand its Syn-One neurodiagnostics platform for detecting neurodegenerative diseases. The funding will accelerate commercial initiatives and product innovation, building on a test already used by over 4,000 clinicians in the United States since 2020. This investment supports the company's goal to integrate the test into a broader multimodal biomarker capability for earlier diagnosis and personalized care.